Thanks for these excellent links. A quick note: regarding the RADAR trial, throughout you write in a way that suggests broad applicability to the population of antipsychotic consumers. The first sentence in particular explicitly includes "every patient taking these medications". But considering the several on and off-label indications of antipsychotics and the prevalence of use in other disorders (especially over here in the states, see eg https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-020-02895-4/tables/3) it might be good to note, outside of the linked title, that the RADAR trial was conducted on patients with schizophrenia only.
Very good point, I should have been more specific. When writing this I only really had patients with psychosis in mind. (Off-label prescribing of antipsychotics is a big issue, in the UK too)
I had a blast reading these thank you
Thanks for these excellent links. A quick note: regarding the RADAR trial, throughout you write in a way that suggests broad applicability to the population of antipsychotic consumers. The first sentence in particular explicitly includes "every patient taking these medications". But considering the several on and off-label indications of antipsychotics and the prevalence of use in other disorders (especially over here in the states, see eg https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-020-02895-4/tables/3) it might be good to note, outside of the linked title, that the RADAR trial was conducted on patients with schizophrenia only.
Very good point, I should have been more specific. When writing this I only really had patients with psychosis in mind. (Off-label prescribing of antipsychotics is a big issue, in the UK too)
I would be very curious to see whether these findings obtain for affective psychosis, too.
Excellent round-up! Onwards we stumble...